These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31519454)

  • 21. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.
    Weber B; Meldgaard P; Hager H; Wu L; Wei W; Tsai J; Khalil A; Nexo E; Sorensen BS
    BMC Cancer; 2014 Apr; 14():294. PubMed ID: 24773774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.
    Evrard SM; Taranchon-Clermont E; Rouquette I; Murray S; Dintner S; Nam-Apostolopoulos YC; Bellosillo B; Varela-Rodriguez M; Nadal E; Wiedorn KH; Melchior L; Andrew E; Jones M; Ridgway J; Frykman C; Lind L; Rot M; Kern I; Speel EJM; Roemen GMJM; Trincheri N; Freiberger SN; Rechsteiner M
    J Mol Diagn; 2019 Nov; 21(6):1010-1024. PubMed ID: 31445213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
    Casula M; Pisano M; Paliogiannis P; Colombino M; Sini MC; Zinellu A; Santeufemia D; Manca A; Casula S; Tore S; Lobrano R; Sardinian Lung Cancer Study Group ; Cossu A; Palmieri G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
    Syed YY
    Mol Diagn Ther; 2016 Apr; 20(2):191-8. PubMed ID: 26891729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
    Song X; Gong J; Zhang X; Feng X; Huang H; Gao M; Chu L
    Br J Cancer; 2020 Oct; 123(9):1437-1444. PubMed ID: 32782293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR mutation testing from liquid biopsy of non-small cell lung cancer at the Institute for Oncology and Radiology of Serbia.
    Cavic M; Krivokuca A; Pavlovic M; Boljevic I; Rakobradovic J; Mihajlovic M; Tanic M; Damjanovic A; Malisic E; Jankovic R
    J BUON; 2020; 25(6):2635-2642. PubMed ID: 33455107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.
    Rathor A; Malik PS; Tanwar P; Khurana S; Baskarane H; Pushpam D; Nambirajan A; Jain D
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):371. PubMed ID: 39066920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).
    Akamatsu H; Koh Y; Okamoto I; Fujimoto D; Bessho A; Azuma K; Morita S; Yamamoto N; Nakagawa K
    Lung Cancer; 2019 May; 131():128-133. PubMed ID: 31027689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2.
    Uchibori K; Takano N; Manabe R; Tsugitomi R; Ogusu S; Tozuka T; Sakamoto H; Yoshida H; Amino Y; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
    Thorac Cancer; 2021 Mar; 12(6):906-913. PubMed ID: 33528892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR detection by liquid biopsy: ripe for clinical usage.
    Batra U; Nathany S; Sharma M; Jain P; Dhanda S; Singh H; Jain A; Mehta A
    Future Oncol; 2022 Jan; 18(1):85-92. PubMed ID: 34704813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
    Song Z; Wang W; Li M; Liu J; Zhang Y
    Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
    Wang W; Song Z; Zhang Y
    Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of Archived Plasma to Detect Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer Patients.
    Oh AC; Lee JK; Kim JY; Jin HO; Jung JW; Chang YH; Hong YJ
    Biopreserv Biobank; 2019 Aug; 17(4):319-325. PubMed ID: 30888199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
    Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
    Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer.
    Claus J; De Smet D; Breyne J; Wesolowski J; Himpe U; Demedts I; Martens GA
    Sci Rep; 2024 Aug; 14(1):18191. PubMed ID: 39107402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2.
    Wu CH; Zhang MS; Huang YL; Cheng WH; Lai JY; Hsieh MS; Liao WY
    Pathol Res Pract; 2024 May; 257():155304. PubMed ID: 38657557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.